Status:

COMPLETED

A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Dengue Fever

Eligibility:

All Genders

6-11 years

Phase:

NA

Brief Summary

This is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years. The...

Detailed Description

This is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years. The...

Eligibility Criteria

Inclusion

  • Children aged 6-11 years at enrollment.
  • Child's parent or legal guardian agrees to provide written informed consent.
  • Child agrees to provide informed assent.
  • Child is enrolled in a public school selected for this trial (and which define the clusters).
  • Child resides within geographic boundaries at least 5 days a week in the cluster area corresponding to his/her school.

Exclusion

  • Children planning to move outside of the cluster boundary within the study period.
  • Child has poor venous access.
  • Child has received an experimental or licensed vaccine against dengue, Zika or chikungunya at enrollment. Participants who received a dengue, Zika or CHIK vaccine after enrollment will not be excluded.
  • Child has any medical condition that would prevent them from completing a blood draw.

Key Trial Info

Start Date :

September 9 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 29 2024

Estimated Enrollment :

5757 Patients enrolled

Trial Details

Trial ID

NCT04514107

Start Date

September 9 2020

End Date

October 29 2024

Last Update

November 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Universidade Federal de Minas Gerais, Instituto de Ciencias Biologicas, Department of Biochemistry and Immunology

Belo Horizonte, Minas Gerais, Brazil, 31275-030